Drug Trial Radar · NCT06920043
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Apr 9, 2025
Primary completion
Jul 3, 2028
Study completion Jul 3, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Conditions
- Metabolic Dysfunction-Associated Steatohepatitis
- Non-alcoholic Fatty Liver Disease
Interventions
EfimosferminDrug
Efimosfermin will be administered as a subcutaneous injection.
PlaceboDrug
Placebo will be administered as a subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent adverse events (TEAEs)Time frame: From Day 1 to 100 weeks
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Chandler, Arizona · Recruiting
GSK Investigational Site
Mesa, Arizona · Recruiting
GSK Investigational Site
Tucson, Arizona · Recruiting
GSK Investigational Site
Fresno, California · Recruiting
GSK Investigational Site
Lancaster, California · Recruiting
GSK Investigational Site
Pasadena, California · Recruiting
GSK Investigational Site
Rialto, California · Recruiting
GSK Investigational Site
Santa Maria, California · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Viera, Florida · Recruiting
GSK Investigational Site
Marietta, Georgia · Recruiting
GSK Investigational Site
Baltimore, Maryland · Recruiting
GSK Investigational Site
Kansas City, Missouri · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
Fayetteville, North Carolina · Recruiting
GSK Investigational Site
Wilson, North Carolina · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
GSK Investigational Site
Dallas, Texas · Recruiting
GSK Investigational Site
Georgetown, Texas · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Pasadena, Texas · Recruiting
GSK Investigational Site
Pearland, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Recruiting
GSK Investigational Site
Waco, Texas · Recruiting
GSK Investigational Site
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.